Per Business Group on Health (via SHRM), 14% of surveyed employers have dropped or plan to drop GLP-1 weight-management coverage by 2027, and the share covering it fell from 72% in 2025 to 60% in 2026. Starbucks is reported to be ending the benefit. Open enrollment is when most people discover the change.
By Dr. SkinnyVIP · Published October 19, 2026 · Quotes link to the original policy or report
“14% of employers have already dropped or plan to drop coverage of GLP-1s for weight management by 2027.”
“coverage dropping from 72% in 2025 to 60% in 2026”
“BGH's survey of 127 employers representing 8.7 million covered U.S. individuals.”
The same survey put pharmacy at 25% of employers' total healthcare spend and projected a 9.2% median cost trend for 2027. SHRM also reported that Starbucks is dropping GLP-1 coverage prescribed for weight loss for its employees, according to reports in October 2026. Earlier in 2026, CVS Caremark put Zepbound back on its main employer formularies, which shows the decision usually sits with the employer, not the insurer.
1. “Does our 2027 plan cover GLP-1 medications for weight management, or only for diabetes?”
2. “If it is being removed, is there a continuation-of-therapy exception for people already on the medication, and until when?”
3. “Is there a capped reimbursement account or a separate weight-management benefit that can be used toward the medication?” (Some employers are replacing coverage with a fixed-budget HRA rather than ending help altogether.)
Get the answers in writing. Benefits teams answer written questions more carefully than hallway ones.
1. Ask your plan one question in writing. “Is there a continuation-of-therapy or medical-necessity exception for members already on a GLP-1, and what documentation does it need?” Many policies keep an exception for diabetes, cardiovascular risk reduction, sleep apnea or liver disease; a letter from your prescriber may qualify you.
2. Check the two public cash-pay routes for the brand-name drug. LillyDirect sells Zepbound to self-pay patients at published prices by dose ($299 to $699 a month for vials as of October 2026, per our Real-Price Index). If you are on Medicare Part D, the Medicare GLP-1 Bridge offers Wegovy or Zepbound for a $50 copay through December 2027 if you meet its criteria (details).
3. If neither fits, know the compounded option's real number. SkinnyVIP's clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership, no subscription and no automatic renewal; you pay once per plan and nothing bills again unless you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. Compounded medications are not FDA-approved products; read how it works and what that means before deciding.
SHRM reports Business Group on Health found 14% of surveyed employers (127 employers, 8.7 million covered people) have dropped or plan to drop GLP-1 coverage for weight management by 2027, with the share covering it falling from 72% in 2025 to 60% in 2026.
SHRM reported in October 2026 that Starbucks is dropping GLP-1 coverage prescribed for weight loss for its employees, according to reports. Confirm the effective date and any transition rules with your benefits team.
Ask about a continuation-of-therapy exception first. If there is none, the published cash-pay routes are LillyDirect's Zepbound self-pay prices, the Medicare GLP-1 Bridge if you are on Part D, or clinician-prescribed compounded tirzepatide, which at SkinnyVIP is $695 for 3 months or $350 for one month with no membership or renewal.
Prescribed weight-management medication is generally an eligible medical expense; many SkinnyVIP patients pay with an HSA or FSA card. Check your plan's rules; we provide itemized receipts.
Ask your plan about exceptions, check the brand-name cash routes, then compare. SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one, any dose, nothing renews.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.